Last reviewed 2026-04-19 · How we verify

Theraflex, BAY 874017

Bayer · Phase 2 active Small molecule

Theraflex, BAY 874017 is a Small molecule drug developed by Bayer. It is currently in Phase 2 development.

At a glance

Generic name	Theraflex, BAY 874017
Sponsor	Bayer
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Theraflex, BAY 874017 CI brief — competitive landscape report
Theraflex, BAY 874017 updates RSS · CI watch RSS
Bayer portfolio CI

Frequently asked questions about Theraflex, BAY 874017

What is Theraflex, BAY 874017?

Theraflex, BAY 874017 is a Small molecule drug developed by Bayer.

Who makes Theraflex, BAY 874017?

Theraflex, BAY 874017 is developed by Bayer (see full Bayer pipeline at /company/bayer).

What development phase is Theraflex, BAY 874017 in?

Theraflex, BAY 874017 is in Phase 2.

Manufacturer: Bayer — full pipeline
Compare: Theraflex, BAY 874017 vs similar drugs
Pricing: Theraflex, BAY 874017 cost, discount & access